(m)UC	(Metastatic) urothelial carcinoma
(N)MIBC	(Non-)muscle-invasive bladder cancer
AEs	Adverse events
≥G3 AE	≥Grade 3 adverse event
irAE	Immune-related adverse event
sAE	Serious adverse event
APC	Antigen-presenting cells
ASCO-GU	Genitourinary Cancers Symposium of the American Society of Clinical Oncology
AUA	American Urologic Association
BC	Bladder cancer
BCG	Bacille Calmette–Guérin
BPS	Bladder-preserving strategies
CEA	Carcinoembryonic antigen
CIS	Carcinoma in situ
ClTr	Clinical trials
CPI	Checkpoint inhibition
CPS	Combined positive score
CR	Complete response
CT	Center of the tumor
CUETO	Club Urologico Español deTratamiento Oncologico
DDM	Dodecyl maltoside
DoR	Duration of response
EAU	European Association of Urology
EBRT	External Beam Radiotherapy of the Bladder
ECOG	Eastern Cooperative Oncology Group
EFS	Event-free survival
EORTC	European Organisation for Research and Treatment of Cancer
FDA	United States Food and Drug Administration
FoxP3	Forkhead box protein P3
FU	Follow up
G1–3	Grading 1–3
LG	Low grade
HG	High grade
GM-CSF	Granulocyte-macrophage colony-stimulating factor
HG-RFS	High-grade recurrence-free survival
I	Immunoscore
i.v.	Intravenously
iCT	Intravesical chemotherapy
IFN	Interferon
IL	Interleukin
IM	Invasive margin
Maint.	Maintenance
MDSC	Myeloid-derived suppressor cells
MHC	Major histocompatibility complex
MMC	Mitomycin C
MUC	Antigens epithelial mucin 1
n.a.	Not applicable
NA	Not available
NKT-cell	Natural killer T-cell
OM	Oportuzumab monatox
PD	Progressive disease
PD-(L)1	Programmed cell death (ligand)-1
PRISMA	Preferred Reporting Items for Systematic Review and Meta-Analysis statement
Rb	Retinoblastom
rBCG	Repeat BCG
RC	Radical cystectomy
RCT	Randomized controlled trial
RECIST	Response evaluation criteria in solid tumors
RR	Risk ratio
SD	Stable disease
TAM	Tumor-associated macrophage
TIL	Tumor-infiltrating lymphocyte
TLR	Toll-like receptor
TMB	Tumor mutational burden
TU	Tumor
TURBT	Transurethral resection of bladder tumor
UTI	Urinary tract infection
Vp	Viral particles
WHO	World Health Organization